Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 15, 2020
Daily News
May 15, 2020
- Novartis’ Tabrecta, Enerzair Up for MHLW Panel Review on May 28
May 15, 2020
- Astellas Sees New Drug Growth Counter Off-Patent Dip in FY2019
May 15, 2020
- Ono Files Opdivo for 1st-Line Treatment for Unresectable Advanced/Recurrent Gastric Cancer
May 15, 2020
- Japan’s First Humira Biosimilar Could Hit Market as Early as November
May 15, 2020
- Infection Society's Updated COVID-19 Guide Includes Information on Veklury
May 15, 2020
- Japan Poised to Quickly Approve Futhan, Actemra, Ivermectin for COVID-19 If Effective: Abe
May 15, 2020
- 400,000 Antigen Test Kits for COVID-19 to Be Supplied by End of May: Health Minister
May 15, 2020
- Suspected COVID-19 Cases to First Receive Antigen Test, Followed by PCR Test if Result is Negative: Suga
May 15, 2020
- COVID-19 Vaccines Too Could Be Filed without Clinical Trial Data: Official
May 15, 2020
- MHLW Urging Novartis to Ensure Speedy Zolgensma Supplies: Sr. Vice Minister
May 15, 2020
- Coefficients for Cost-Based Pricing Formula Updated: Chuikyo
May 15, 2020
- Sumitomo Dainippon to Upscale Digital Info Provisioning, Face-to-Face Approach also Important: President
May 15, 2020
- Astellas Taking Flexible Approaches towards Patients Enrolled in Clinical Studies amid COVID-19 Pandemic
May 15, 2020
- Denka to Start Production of Raw Material for Avigan from May 16
May 15, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…